Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 7, 2014, Pages 1486-1494

  Lakshmikanthan, Sribalaji ^a   Zieba, Bartosz J ^b,d   Ge, Zhi Dong ^c   Momotani, Ko ^b   Zheng, Xiaodong ^c,e   Lund, Hayley ^c   Artamonov, Mykhaylo V ^b   Maas, Jason E ^c   Szabo, Aniko ^c   Zhang, David X ^c   Auchampach, John A ^c   Mattson, David L ^c   Somlyo, Avril V ^b   Chrzanowska Wodnicka, Magdalena ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

relaxation; signal transduction; vasodilation

Indexed keywords

CYCLIC AMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; LOSARTAN; PHENYLEPHRINE; PHOSPHATASE; PROTEIN DERIVATIVE; PROTEIN RAP1B; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; ENDOTHELIUM; HEART RATE; HEART VENTRICLE HYPERTROPHY; KIDNEY FUNCTION; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; VASODILATATION;

RELAXATION; SIGNAL TRANSDUCTION; VASODILATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RAP GTP-BINDING PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84903159007     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303678     Document Type: Article

References (55)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
2. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208-2216.
3. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
4. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol. 1996;133:1403-1415.
5. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.
6. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda). 2009;24:342-356.
7. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol. 2009;10:53-62.
8. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
9. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996;93:13176-13181.
10. Frische EW, Zwartkruis FJ. Rap1, a mercenary among the Ras-like GTPases. Dev Biol. 2010;340:1-9.
11. Chrzanowska-Wodnicka M. Distinct functions for rap1 signaling in vascular morphogenesis and dysfunction. Exp Cell Res. 2013;319:2350-2359.
12. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC II. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115:680-687.
13. Duchniewicz M, Zemojtel T, Kolanczyk M, Grossmann S, Scheele JS, Zwartkruis FJ. Rap1A-deficient T and B cells show impaired integrinmediated cell adhesion. Mol Cell Biol. 2006;26:643-653.
14. Li Y, Yan J, De P, et al. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol. 2007;179:8322-8331.
15. Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC II, Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008;111:2647-2656.
16. Yan J, Li F, Ingram DA, Quilliam LA. Rap1a is a key regulator of fibroblast growth factor 2-induced angiogenesis and together with Rap1b controls human endothelial cell functions. Mol Cell Biol. 2008;28:5803-5810.
17. Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, Ramchandran R, Chrzanowska-Wodnicka M. Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin ?v?3. Blood. 2011;118:2015-2026.
18. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
19. Liu L, Wang W, Meng X, Gao J, Wu H, Wang P, Wu W, Wang L, Ma L, Zhang W. Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan-a proteomic analysis. J Physiol Biochem. 2010;66:329-338.
20. Zhang GX, Kimura S, Murao K, Yu X, Obata K, Matsuyoshi H, Takaki M. Effects of angiotensin type I receptor blockade on the cardiac Raf/ MEK/ERK cascade activated via adrenergic receptors. J Pharmacol Sci. 2010;113:224-233.
21. Hilker RR, Rhoads PS, Billings CE. Clinical use of hydralazine and hexamethonium in treatment of hypertension. J Am Med Assoc. 1953;153:5-9.
22. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 1974;35:775-781.
23. Leenen FH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med. 1987;82:969-978.
24. Fogari R, Zoppi A, Mugellini A, Tettamanti F, Lusardi P, Corradi L. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J. 1995;16:1120-1125.
25. Fox JG, Barthold S, Davisson M, Newcomer CE, Quimby FW, Smith A. The Mouse in Biomedical Research: Normative Biology, Husbandry, and Models. Waltham, MA: Academic Press; 2006.
26. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int. 2007;71:266-271.
27. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA. 1996;276:1186-1188.
28. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension. 2004;43:364-369.
29. Zieba BJ, Artamonov MV, Jin L, Momotani K, Ho R, Franke AS, Neppl RL, Stevenson AS, Khromov AS, Chrzanowska-Wodnicka M, Somlyo AV. The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity. J Biol Chem. 2011;286:16681-16692.
30. Gendron L, Oligny JF, Payet MD, Gallo-Payet N. Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem. 2003;278:3606-3614.
31. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res. 1998;82:666-676.
32. Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183-190.
33. Weisbrod RM, Griswold MC, Yaghoubi M, Komalavilas P, Lincoln TM, Cohen RA. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol. 1998;125:1695-1707.
34. Dekkers BG, Racké K, Schmidt M. Distinct PKA and Epac compartmentalization in airway function and plasticity. Pharmacol Ther. 2013;137:248-265.
35. Guo FF, Kumahara E, Saffen D. A CalDAG-GEFI/Rap1/B-Raf cassette couples M(1) muscarinic acetylcholine receptors to the activation of ERK1/2. J Biol Chem. 2001;276:25568-25581.
36. Ramadoss J, Pastore MB, Magness RR. Endothelial caveolar subcellular domain regulation of endothelial nitric oxide synthase. Clin Exp Pharmacol Physiol. 2013;40:753-764.
37. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146-2152.
38. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837, 837a.
39. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
40. Chen Y, Yu M, Podd A, Wen R, Chrzanowska-Wodnicka M, White GC, Wang D. A critical role of Rap1b in B-cell trafficking and marginal zone B-cell development. Blood. 2008;111:4627-4636.
41. Chu H, Awasthi A, White GC II, Chrzanowska-Wodnicka M, Malarkannan S. Rap1b regulates B cell development, homing, and T cell-dependent humoral immunity. J Immunol. 2008;181:3373-3383.
42. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011;17:1402-1409.
43. Beierwaltes WH, Harrison-Bernard LM, Sullivan JC, Mattson DL. Assessment of renal function; clearance, the renal microcirculation, renal blood flow, and metabolic balance. Compr Physiol. 2013;3:165-200.
44. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H1235-H1248.
45. Yamada T, Sakisaka T, Hisata S, Baba T, Takai Y. RA-RhoGAP, Rapactivated Rho GTPase-activating protein implicated in neurite outgrowth through Rho. J Biol Chem. 2005;280:33026-33034.
46. Jeon CY, Kim HJ, Morii H, Mori N, Settleman J, Lee JY, Kim J, Kim SC, Park JB. Neurite outgrowth from PC12 cells by basic fibroblast growth factor (bFGF) is mediated by RhoA inactivation through p190RhoGAP and ARAP3. J Cell Physiol. 2010;224:786-794.
47. Aivatiadou E, Ripolone M, Brunetti F, Berruti G. cAMP-Epac2-mediated activation of Rap1 in developing male germ cells: RA-RhoGAP as a possible direct down-stream effector. Mol Reprod Dev. 2009;76:407-416.
48. Moon MY, Kim HJ, Kim JG, Lee JY, Kim J, Kim SC, Choi IG, Kim PH, Park JB. Small GTPase Rap1 regulates cell migration through regulation of small GTPase RhoA activity in response to transforming growth factor-?1. J Cell Physiol. 2013;228:2119-2126.
49. Saras J, Franzén P, Aspenström P, Hellman U, Gonez LJ, Heldin CH. A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1. J Biol Chem. 1997;272: 24333-24338.
50. Post A, Pannekoek WJ, Ross SH, Verlaan I, Brouwer PM, Bos JL. Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci U S A. 2013;110:11427-11432.
51. Laurent AC, Breckler M, Berthouze M, Lezoualc'h F. Role of Epac in brain and heart. Biochem Soc Trans. 2012;40:51-57.
52. Morel E, Marcantoni A, Gastineau M, Birkedal R, Rochais F, Garnier A, Lompré AM, Vandecasteele G, Lezoualc'h F. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res. 2005;97:1296-1304.
53. Metrich M, Lucas A, Gastineau M, Samuel J-L, Heymes C, Morel E, Lezoualc'h F. Epac mediates {beta}-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res. 2008;102:959-965.
54. Métrich M, Laurent AC, Breckler M, Duquesnes N, Hmitou I, Courillau D, Blondeau JP, Crozatier B, Lezoualc'h F, Morel E. Epac activation induces histone deacetylase nuclear export via a Ras-dependent signalling pathway. Cell Signal. 2010;22:1459-1468.
55. Zhang X, Szeto C, Gao E, et al. Cardiotoxic and cardioprotective features of chronic ?-adrenergic signaling. Circ Res. 2013;112:498-509.